SCHARC Treatment for Advanced Head and Neck Cancer
Author Information
Author(s): Peter Stadler, Kurt Putnik, Thore Kreimeyer, Lisa D Sprague, Oliver Koelbl, Christof Schäfer
Primary Institution: University Hospital Regensburg
Hypothesis
Does the SCHARC protocol improve overall survival in patients with advanced head and neck cancer?
Conclusion
The SCHARC protocol was effective in patients diagnosed with advanced head and neck cancer, leading to long-term disease control and survival in about 50% of the patients.
Supporting Evidence
- The estimated 3-year overall survival rate was 57%.
- Patients with a hemoglobin nadir above 10.2 g/dl had a significantly better survival rate.
- Acute grade 2-3 mucositis occurred in 80% of patients.
Takeaway
Doctors used a special treatment called SCHARC to help people with serious throat and mouth cancers, and it worked for about half of them.
Methodology
The study analyzed 64 patients who received the SCHARC protocol from 1997 to 2004, assessing their survival and treatment outcomes.
Potential Biases
Potential bias due to protocol deviations and the retrospective nature of the analysis.
Limitations
The study was retrospective and not a formal clinical trial, which may affect the reliability of the findings.
Participant Demographics
Patients were mostly male (86%), with a mean age of 56 years; 88% were stage IV cancer.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website